Nota de prensa


Oxolife, the Women’s Reproductive Health R&D biotech, has been awarded with a 2.4M€ grant from the Spanish Science and Innovation Ministry (Plan Estatal de Investigación Científica) to develop a new treatment for infertility related to polycystic ovarian syndrome (PCOS).

Oxolife, in collaboration with Cordoba’s University, plans to progress in the next 2 years from preclinical stages to a phase II clinical trial in PCOS patients. PCOS is an endocrine disease affecting up to 13% of women of childbearing age, causing infertility in most of them (>70%).

Unfortunately, current medical management, based on restoring ovulatory function or metabolic status, cannot meet the expectations of women and couples, since more than 60% cannot become pregnant with available treatments.

Oxolife is developing a unique new treatment designed to restore the reproductive system in a single intervention, with the potential to overcome the limitations of current strategies in PCOS.

Ignasi Canals, Oxolife’s CSO, states, “This grant speeds up a promising line of research that targets ovarian dysfunction, endometrial receptivity, and the metabolic status, tackling the syndrome in a holistic way. We’re encouraged to provide a solution for women and couples suffering from PCOS, in a short period” Oxolife, with its pipeline, achieves a prominent position within the Women’s Reproductive Health biotech sector.

Oxolife’s CEO and CMO, Agnes Arbat, declares: “With a pharmaceutical compound that increases embryo implantation already in phase II human trials, and a unique late-stage preclinical asset for infertility related to PCOS, we cover the most prevalent causes of female infertility.

We’re now in a privileged position, enlarging the pipeline and transferring projects from early stages to late development of consistent and convenient products, bringing new solutions to patients”.

Oxolife is a biotechnology company based in Parc Científic de Barcelona, focused and committed to improving female fertility and women’s health. The company was founded in 2013 by Dr. Agnès Arbat and Dr. Ignasi Canals, both experienced professionals with a background in the pharmaceutical industry and research. The company centers its R&D plans on identify and develop new treatments for Women’s Reproductive Health. Current main assets include the development of OXO-001, a molecule that acts directly in the endometrium to increase embryo implantation and the pregnancy success rates. This development is in the advanced Phase II stages. A second target is infertility related to Polycystic Ovary Syndrome. Oxolife has been awarded with the “Seal of Excellence” from the European Commission and has received research grants from EIT Health and the Spanish Government.

Nuevos informes, publicaciones y series de datos: El Capital riesgo Informal en España 2022 / Informe de Impacto Económico y Social de los préstamos otorgados por Enisa / Suscríbete a la newsletter con las noticias destacadas de cada semana / Serie de datos (excel) de Grupos-Redes Business Angels, aceleradoras-incubadoras. 2021

Webcapitalriesgo.com está patrocinada por Quantum Capital Partners

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos requeridos están marcados *

Publicar comentario